ZimVie’s Acquisition by ARCHIMED

On July 21, 2025, ZimVie Inc. (“ZimVie”), a global life sciences leader in the dental implant market, announced their entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED (“ARCHIMED”), an investment firm focused exclusively on healthcare industries. Under the terms of the merger agreement, ZimVie stockholders will receive $19.00 in cash for each share of ZimVie common stock outstanding at the closing of the transaction, corresponding to an enterprise value of approximately $730 million. Cravath is representing ZimVie in connection with the transaction.

The Cravath team is led by partners Robert I. Townsend III and Matthew G. Jones and includes of counsel Patrick S. Taylor and associates Monica He, W. Peter Kim, Colin L. Halvey, Nigle B. Barrow III, Weston James Barker and Ryan W. Herrmann on M&A matters; partner Christopher J. Kelly and associates Gene Choi and Kiyon Hahm on financing matters; partner J. Leonard Teti II and associate Megan Samayoa on tax matters; partner Jonathan J. Katz and associates Brendon J. Rivard and Keanna N. Joseph on executive compensation and benefits matters; partner David J. Kappos, of counsel Kathryn-Ann Stamm and associate Yunhao (Leslie) Liu on intellectual property matters; partners Margaret T. Segall and Jesse M. Weiss and associate Lavinia M. Hecht on antitrust matters; partner Daniel Slifkin, of counsel Flora Ng and associate Noah Rothman on litigation matters; partner Matthew Morreale and associate Star S. Gulant on environmental matters; and senior attorney Joyce Law and practice area attorney Lauren Piechocki on real estate matters. Simi Fajemisin also worked on antitrust matters, summer associate Daniel Kim also worked on M&A matters and summer associate Michael Christopher Spivey also worked on litigation matters.